Abstract.
Osteoarthritis (OA) is a painful and degenerating progressive disease of the joints which affects millions of patients worldwide. The cause of OA is largely unknown. Among the potential therapies for the symptomatic treatment of OA, the intra-articular administration of a specific bradykinin (BK) B2 receptor antagonist has been reported to produce a long lasting analgesic effect in patients affected by knee OA. BK is a vasodilator and inflammatory nonapeptide which is generated in OA synovium. It contributes to the initiation and maintenance of inflammation, to exciting and sensitizing sensory nerve fibres, thus producing pain, and to activating synoviocytes and chondrocytes which are the main cells involved in the homeostasis of synovial fluid and cartilage, respectively. Moreover, BK synergistically potentiates the effects produced by pro-inflammatory cytokines. Biochemical and preclinical evidence supporting the therapeutic relevance of B2 receptor blockade in OA pathophysiology are reviewed in this publication.
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Additional information
Received 26 October 2007; returned for revision 18 December 2007; received from final revision 17 January 2008; accepted by J. Di Battista 17 January 2008
Rights and permissions
About this article
Cite this article
Meini, S., Maggi, C.A. Knee osteoarthritis: a role for bradykinin?. Inflamm. res. 57, 351–361 (2008). https://doi.org/10.1007/s00011-007-7204-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00011-007-7204-1